This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imai, M. Articles by Tomlinson, S. Search for Related Content PubMed PubMed Citation Articles by Imai, M. Articles by Tomlinson, S.

Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer

¹ Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina and ² Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York

Requests for reprints: Stephen Tomlinson, Department of Microbiology and Immunology, Medical University of South Carolina, BSB 201, 173 Ashley Avenue, Charleston, SC 29424. Phone: 843-792-1450; Fax: 843-792-2464; E-mail: tomlinss{at}musc.edu.

The role of complement in antibody therapy of cancer is in general poorly understood. We used the EL4 syngeneic mouse model of metastatic lymphoma to investigate the role of complement in immunotherapy directed against GD2, a target of clinical relevance. IgG2a and IgM anti-GD2 therapy protected EL4-challenged mice from metastases and prolonged survival. Expression of CD59, an inhibitor of direct complement-mediated cytotoxicity (CMC), effectively protected EL4 cells from CMC in vitro but did not affect the outcome of monoclonal antibody therapy. Protection by IgG therapy was also unaffected in mice deficient in C3 or complement receptor 3 (CR3) but was almost completely abrogated in FcR I/III–deficient mice. These data indicate a crucial role for antibody-dependent cell-mediated cytoxicity (ADCC). However, at lower doses of IgG, therapeutic effect was partially abrogated in C3-deficient mice, indicating complement-mediated enhancement of ADCC at limiting IgG concentration. In contrast to IgG, the therapeutic effect of IgM was completely abrogated in C3-deficient mice. High level expression of CD59 on EL4 did not influence IgM therapy, suggesting IgM functions by complement-dependent cell-mediated cytotoxicity (CDCC), a mechanism thought to be inactive against tumor cells. Thus, IgG and IgM can operate via different primary mechanisms of action, and CDCC and complement-dependent enhancement of ADCC mechanisms are operative in vivo. The effects of complement can be supplemental to other antibody-mediated mechanisms and likely have increased significance at limiting antibody concentration or low antigen density.

This article has been cited by other articles:

				R. M. Donev, L. C. Gray, B. Sivasankar, T. R. Hughes, C. W. van den Berg, and B. P. Morgan Modulation of CD59 Expression by Restrictive Silencer Factor-Derived Peptides in Cancer Immunotherapy for Neuroblastoma Cancer Res., July 15, 2008; 68(14): 5979 - 5987. [Abstract] [Full Text] [PDF]

				M. Imai, R. Ohta, J. C. Varela, H. Song, and S. Tomlinson Enhancement of Antibody-Dependent Mechanisms of Tumor Cell Lysis by a Targeted Activator of Complement Cancer Res., October 1, 2007; 67(19): 9535 - 9541. [Abstract] [Full Text] [PDF]

				N. Alvarez-Rueda, S. Leprieur, B. Clemenceau, S. Supiot, V. Sebille-Rivain, A. Faivre-Chauvet, F. Davodeau, F. Paris, J. Barbet, J. Aubry, et al. Binding Activities and Antitumor Properties of a New Mouse/Human Chimeric Antibody Specific for GD2 Ganglioside Antigen Clin. Cancer Res., September 15, 2007; 13(18): 5613s - 5620s. [Abstract] [Full Text] [PDF]

				M. Mizukami, T. Hanagiri, M. Yasuda, K. Kuroda, Y. Shigematsu, T. Baba, T. Fukuyama, Y. Nagata, T. So, Y. Ichiki, et al. Antitumor Effect of Antibody against a SEREX-Defined Antigen (UOEH-LC-1) on Lung Cancer Xenotransplanted into Severe Combined Immunodeficiency Mice Cancer Res., September 1, 2007; 67(17): 8351 - 8357. [Abstract] [Full Text] [PDF]

				G. Raval, S. Biswas, P. Rayman, K. Biswas, G. Sa, S. Ghosh, M. Thornton, C. Hilston, T. Das, R. Bukowski, et al. TNF-{alpha} Induction of GM2 Expression on Renal Cell Carcinomas Promotes T Cell Dysfunction J. Immunol., May 15, 2007; 178(10): 6642 - 6652. [Abstract] [Full Text] [PDF]

				D. Ajona, Y.-F. Hsu, L. Corrales, L. M. Montuenga, and R. Pio Down-Regulation of Human Complement Factor H Sensitizes Non-Small Cell Lung Cancer Cells to Complement Attack and Reduces In Vivo Tumor Growth J. Immunol., May 1, 2007; 178(9): 5991 - 5998. [Abstract] [Full Text] [PDF]